Antisecretory Factor Glioblastoma Phase 2

Summary

This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis

Interventions

• Salovum · DIETARY_SUPPLEMENT

  Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.

• Placebo egg yolk powder · DIETARY_SUPPLEMENT

  Egg yolk powder derived from hen fed with normal feed.

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

1. Pathology verified glioblastoma or astrocytoma grade 4
2. Age 18-75 years
3. Surgical treatment-resection.
4. Scheduled concomitant radiochemotherapy, or only chemotherapy.
5. Informed consent

Exclusion Criteria:

1. No informed consent
2. Egg yolk allergy
3. Only surgical biopsy
4. Only radiotherapy

Sites (1)

• Skåne University Hospital, Lund, Sweden · RECRUITING